DISEASE CHARACTERISTICS:

• Diagnosis of solid tumor

  • Advanced or metastatic disease* NOTE: *With the exception of colorectal and lung cancer patients, all patients must receive approval from the insurance carrier that allows for coverage/payment of the study drug bevacizumab
• Refractory to standard therapy OR no standard therapy exists
• No advanced ovarian cancer or peritoneal carcinomatosis
• No metastases from any cancer causing significant ascites

• No lung malignancy with any of the following characteristics:

  • In close proximity to a major vessel
  • Centrally located
  • Cavitary
  • Squamous histology
  • Hemoptysis > ½ teaspoon per day

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1
• Platelet count ≥ 100,000/mm^3
• Absolute neutrophil count ≥ 1,500/mm^3
• Bilirubin < 2 mg/dL
• AST or ALT < 3 times upper limit of normal
• Creatinine < 2 mg/dL
• Urine protein:creatinine ratio ≤ 1.0
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Able to tolerate oral therapy
• No bleeding diatheses or coagulopathy
• No impairment of gastrointestinal (GI) function or GI disease that may affect or alter absorption of imatinib mesylate and/or cyclophosphamide (e.g., malabsorption syndrome, history of total gastrectomy/significant small bowel resection)
• No abdominal fistula, GI perforation, or intra-abdominal abscess within the past 6 months
• No uncontrolled hypertension (i.e., blood pressure > 150/100 mm Hg)

• No uncontrolled cardiovascular disease, including any of the following:

  • Coronary artery disease
  • Uncontrolled cardiac arrhythmia
  • Symptomatic congestive heart failure (i.e., New York Heart Association class II-IV)
  • Unstable angina pectoris
  • Clinically significant peripheral vascular disease

• No arterial thromboses within the past year, including any of the following:

  • Transient ischemic attack
  • Myocardial infarction
  • Cerebrovascular event
  • Unstable angina
  • Angina requiring medical or surgical intervention
  • Clinically significant peripheral artery disease
  • Any other arterial thromboembolic event
• No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
• No serious nonhealing wound, ulcer, or bone fracture
• No other active second malignancy except nonmelanoma skin cancer or cervical carcinoma in situ unless therapy has been completed and < 30% risk for relapse exists
• No active infection or known HIV infection
• No history of allergic reactions (≥ grade 3 or 4) to compounds of similar chemical or biologic composition to cyclophosphamide (i.e., alkylating agents)
• No history of noncompliance with medical regimens
• No known intolerance or hypersensitivity reaction to bevacizumab, imatinib mesylate, or cyclophosphamide
• No other significant medical illness, psychiatric illness, or social situation that, in the opinion of the investigator, would limit compliance with study requirements
• No inability to grant reliable informed consent

PRIOR CONCURRENT THERAPY:

• No major surgical procedure within the past 28 days or anticipated major surgery during study treatment except for placement of a venous access device or surgery for a diagnostic study